RxDoctor Payments Data

Stephanie Baukus

Internal Medicine · Lansing, MINPI 1578981189

Payments from drug & device makers

$3,694in general payments, 2019–2025

Across 203 payments — averaging $18.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$639
  • Johnson & Johnson$333
  • Astellas Pharma US Inc$285
  • Merck$216
  • Welch Allyn$192
  • Gilead$183
  • plus $2K from 34 others

What the payments were for

  • Food & beverage$3,29389%
  • Education$2106%
  • Other$1925%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,694 in reported general payments places this provider in the 85th percentile of 4,567 internal medicine providers in Michigan.

See all internal medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$24,715
Medicare patients
142
Services billed
292

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin37$57,011
OzempicSemaglutide24$43,781
TrulicityDulaglutide20$36,035
MounjaroTirzepatide18$22,012
EliquisApixaban11$16,031
Atorvastatin Calcium281$3,983
Levothyroxine Sodium242$3,958
Arnuity ElliptaFluticasone Furoate11$2,231
Losartan Potassium150$1,929
Novolog Mix 70-30Insulin Aspart Prot/Insuln Asp12$1,647
Zolpidem Tartrate22$1,540
SynthroidLevothyroxine Sodium13$1,512
Omeprazole92$1,317
Amlodipine Besylate143$1,144
Rosuvastatin Calcium59$964

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$169$58,04738 claims
Boehringer IngelheimJardiance$51$57,01137 claims
Novo NordiskOzempic, Novolog Mix 70-30$639$45,42836 claims
PfizerEliquis$138$16,03111 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$16$3,958242 claims
AbbVieSynthroid$32$1,51213 claims
Almatica Pharma LLCSertraline Hcl$14$59948 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,567 internal medicine providers in Michigan.

Other internal medicine in Lansing

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →